Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Elevated lactate dehydrogenase is an adverse predictor of outcome in HLA-matched sibling bone marrow transplant for acute myelogenous leukemia

Bone Marrow Transplantation volume 40, pages 753–758 (2007)Cite this article

Abstract

Prognostic factors for survival following allogeneic BMT for AML include age, disease status and cytogenetic risk classification. Lactate dehydrogenase (LDH) levels have not been studied as a potential risk factor. We reviewed our experience with BMT for AML and included LDH at the time of admission in an analysis of prognostic factors for survival. We found that LDH >330 U/l (1.5 times the upper limit of normal at our institution), older age, active disease, peripheral stem cell graft and male-to-male transplant were significant adverse predictors of survival. After accounting for LDH, other factors such as disease status and cytogenetics were not significantly associated with the outcome of BMT. All but one patient with an LDH >330 U/l had active disease. However, when patients in CR were excluded, LDH >330 U/l remained a significant adverse predictor of overall survival (hazard ratio 2.70, 95% confidence interval 1.41–5.16, P=0.003). We conclude that LDH is an important adverse risk factor for survival and should be included in future studies of risk performed on larger patient cohorts.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Yanada M, Matsuo K, Emi N, Naoe T . Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission. Cancer 2005; 103: 1652–1658.

    Article  PubMed  Google Scholar 

  2. Ferrant A, Labopin M, Frassoni F, Prentice HG, Cahn JY, Blaise D et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation Study. Blood 1997; 90: 2931–2938.

    CAS  PubMed  Google Scholar 

  3. Gale RP, Horowitz MM, Weiner RS, Ash RC, Atkinson K, Babu R et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant 1995; 16: 203–208.

    CAS  PubMed  Google Scholar 

  4. Keating S, Suciu S, de Witte T, Mandelli F, Willemze R, Resegotti L et al. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’ Adulto (GIMEMA) Leukemia Cooperative Groups. Bone Marrow Transplant 1996; 17: 993–1001.

    CAS  PubMed  Google Scholar 

  5. Grigg AP, Szer J, Beresford J, Dodds A, Bradstock K, Durrant S et al. Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia. Br J Haematol 1999; 107: 409–418.

    Article  CAS  PubMed  Google Scholar 

  6. Frassoni F, Labopin M, Powles R, Mary JY, Arcese W, Bacigalupo A et al. Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 2000; 355: 1393–1398.

    Article  CAS  PubMed  Google Scholar 

  7. Michallet M, Thomas X, Vernant JP, Kuentz M, Socie G, Espérou-Bourdeau H et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM). Bone Marrow Transplant 2000; 26: 1157–1163.

    Article  CAS  PubMed  Google Scholar 

  8. Biggs JC, Horowitz MM, Gale RP, Ash RC, Atkinson K, Helbig W et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 1992; 80: 1090–1093.

    CAS  PubMed  Google Scholar 

  9. Blum W, Bolwell BJ, Phillips G, Farag SS, Lin TS, Avalos BR et al. High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation. Biol Blood Marrow Transplant 2006; 12: 61–67.

    Article  PubMed  Google Scholar 

  10. Sierra J, Storer B, Hansen JA, Bjerke JW, Martin PJ, Petersdorf EW et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 1997; 89: 4226–4235.

    CAS  PubMed  Google Scholar 

  11. Haferlach T, Schoch C, Loffler H, Gassmann W, Kern W, Schnittger S et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group Studies 10.1200/JCO.2003.08.00. J Clin Oncol 2003; 21: 256–265.

    Article  PubMed  Google Scholar 

  12. Abou-Jawde R, Sobecks R, Pohlman B, Rybicki L, Advani A, Sekeres M et al. The role of post-remission chemotherapy for older patients with acute myelogenous leukemia. Leuk Lymphoma 2006; 47: 689–695.

    Article  CAS  PubMed  Google Scholar 

  13. Ferrara F, Mirto S . Serum LDH as a predictor of clinical outcome in acute myelogenous leukaemia of the elderly. Br J Haematol 1996; 92: 627–631.

    Article  CAS  PubMed  Google Scholar 

  14. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000; 96: 4075–4083.

    CAS  PubMed  Google Scholar 

  15. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325–4336.

    Article  CAS  PubMed  Google Scholar 

  16. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322–2333.

    CAS  PubMed  Google Scholar 

  17. Farag SS, Bolwell BJ, Elder PJ, Kalaycio M, Lin T, Pohlman B et al. High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia. Bone Marrow Transplant 2005; 35: 653–661.

    Article  CAS  PubMed  Google Scholar 

  18. Bolwell BJ, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski L et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 34: 621–625.

    Article  CAS  PubMed  Google Scholar 

  19. von Eyben FE, Blaabjerg O, Hyltoft-Petersen P, Madsen EL, Amato R, Liu F et al. Serum lactate dehydrogenase isoenzyme 1 and prediction of death in patients with metastatic testicular germ cell tumors. Clin Chemistry Lab Med 2001; 39: 38–44.

    CAS  Google Scholar 

  20. Anonymous. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594–603.

    Article  Google Scholar 

  21. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258–1265.

    Article  CAS  PubMed  Google Scholar 

  22. Anonymous. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994.

    Article  Google Scholar 

  23. Lassen UN, Osterlind K, Hirsch FR, Bergman B, Dombernowsky P, Hansen HH . Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression. Br J Cancer 1999; 79: 515–519.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Bolwell B, Kalaycio M, Sobecks R, Andresen A, McBee M, Kuczkowski L et al. Autologous hematopoietic cell transplantation for non-Hodgkin's lymphoma: 100 month follow-up. Bone Marrow Transplant 2002; 29: 673–679.

    Article  CAS  PubMed  Google Scholar 

  25. Copelan EA, Penza SL, Pohlman B, Avalos BR, Goormastic M, Andresen S et al. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2000; 25: 1243–1248.

    Article  CAS  PubMed  Google Scholar 

  26. Mehta J, Gordon LI, Tallman MA, Winter JN, Evens AO, Frankfurt O et al. Does younger age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially? Bone Marrow Transplant 2006; 38: 95–100.

    Article  CAS  PubMed  Google Scholar 

  27. Atkinson K, Farrell C, Chapman G, Downs K, Penny R, Biggs J . Female marrow donors increase the risk of acute graft-versus-host disease: effect of donor age and parity and analysis of cell subpopulations in the donor marrow inoculum. Br J Haematol 1986; 63: 231–239.

    Article  CAS  PubMed  Google Scholar 

  28. Swansbury GJ, Lawler SD, Alimena G, Arthur D, Berger R, Van den Berghe H et al. Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet 1994; 73: 1–7.

    Article  CAS  PubMed  Google Scholar 

  29. Couban S, Simpson DR, Barnett MJ, Bredeson C, Hubesch L, Howson-Jan K et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 100: 1525–1531.

    Article  CAS  PubMed  Google Scholar 

  30. Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 2000; 95: 3702–3709.

    CAS  PubMed  Google Scholar 

  31. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175–181.

    Article  CAS  PubMed  Google Scholar 

  32. Sekeres M, Stone RM . Older adults with acute myeloid leukemia. Current Oncol Rep 2002; 4: 403–409.

    Article  Google Scholar 

  33. Jourdan E, Boiron J-M, Dastugue N, Vey N, Marit G, Rigal-Huguet F et al. Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience. J Clin Oncol 2005; 23: 7676–7684.

    Article  PubMed  Google Scholar 

  34. Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial. Blood 2003; 102: 1232–1240.

    Article  CAS  PubMed  Google Scholar 

  35. Chalandon Y, Barnett MJ, Horsman DE, Conneally EA, Nantel SH, Nevill TJ et al. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant 2002; 8: 435–443.

    Article  PubMed  Google Scholar 

  36. Obenchain R, Ruffner K, Stokes D, Wu W, Brandt S, Chinratanalab W et al. Allogeneic hematopoietic stem cell transplant (HSCT) in adults with acute myeloid leukemia (AML)—a single program experience. Biol Blood Marrow Transplant 2006; 12: 88.

    Article  Google Scholar 

  37. Clift RA, Buckner CD, Appelbaum FR, Schoch G, Petersen FB, Bensinger WI et al. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 1992; 10: 1723–1729.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematologic Oncology and Blood Disorders, The Cleveland Clinic, Taussig Cancer Center, Cleveland, OH, USA

    M Kalaycio, B Pohlman, R Dean, J Sweetenham, S Andresen, R Sobecks, M A Sekeres, A Advani, S Brown & B Bolwell

  2. Department of Quantitative Health Sciences, Cleveland, OH, USA

    L Rybicki

Authors
  1. M Kalaycio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Rybicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B Pohlman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Dean
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Sweetenham
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Andresen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Sobecks
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M A Sekeres
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A Advani
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. B Bolwell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Kalaycio.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kalaycio, M., Rybicki, L., Pohlman, B. et al. Elevated lactate dehydrogenase is an adverse predictor of outcome in HLA-matched sibling bone marrow transplant for acute myelogenous leukemia. Bone Marrow Transplant 40, 753–758 (2007). https://doi.org/10.1038/sj.bmt.1705811

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705811

Keywords

This article is cited by

Search

Advanced search

Quick links